LONDON: hVIVO plc, a leading early-stage Contract Research Organisation specializing in human challenge clinical trials, announced the acquisition of Cryo-Store Limited for up to £3.2 million. The deal includes £2.7 million funded from hVIVO’s existing cash resources and up to £0.5 million in equity, subject to certain terms. Founded in 1999, Cryo-Store provides off-site, temperature-controlled…
All posts tagged hVIVO
hVIVO acquires CRS units for €10 million
LONDON: hVIVO plc, a leading human challenge clinical trials organization, has acquired two clinical research units from German CRO CRS Clinical Research Services Management GmbH for €10 million. The Mannheim and Kiel units, known for cardiometabolic, immunology, and renal trials, add 120 beds to hVIVO’s capacity. The acquisition enhances hVIVO’s Phase I and II trials…
Data shows SARS-CoV-2 human challenge studies safe in healthy young adults
Open Orphan plc (AIM: ORPH), a rapidly growing specialist contract research organisation (CRO) and world leader in testing infectious and respiratory disease products using human challenge clinical trials, announces the results from the world’s first COVID-19 characterisation study, which was a partnership between hVIVO, Imperial College London, the Vaccine Taskforce and Department of Health and Social Care…
Open Orphan’s hVIVO to manufacture a SARS-CoV-2 challenge virus
LONDON: hVIVO, a subsidiary of Open Orphan plc (LON: ORPH), has signed a contract with Imperial College London, as part of a Wellcome Trust funded initiative to manufacture a SARS-CoV-2 challenge virus. The contract is worth £3 million and under this agreement hVIVO will develop a new SARS-CoV-2 challenge virus based on new emerging variants…